An interventional study of Active Intermittent Theta Burst Stimulation and Online Cognitive Training in Bipolar Disorder (BD) and Cognitive Impairment, sponsored by First Affiliated Hospital of Zhejiang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University — 8 open to participants now, 8 under way, none of them phase 3. Bipolar Disorder · First Affiliated Hospital of Zhejiang University.
Among the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 11th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →8 of the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University are open now, in 1 country. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–45
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–45
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 15–55 · Healthy volunteers
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
By country, each count listing its studies:
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 94 across the 12 interventional studies, 960 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.
4 of the studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07021508First Affiliated Hospital of Zhejiang UniversityEfficacy and Safety Assessment of Temporal Interference Stimulation to Improve Bipolar Depression | 2026-12 |
| NCT07589647First Affiliated Hospital of Zhejiang UniversityResearch on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
| NCT07414147First Affiliated Hospital of Zhejiang UniversityTMS for Improving Cognitive Function in Bipolar Disorder | 2027-03-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Bipolar disorder is a highly disabling psychiatric illness, and cognitive impairment is common in patients with bipolar depression as well as during remission, contributing substantially to functional disability and poorer prognosis. Currently, effective interventions specifically targeting cognitive deficits remain limited, highlighting the need for novel treatment strategies. Transcranial magnetic stimulation, a noninvasive neuromodulation technique, has shown potential benefits for depressive symptoms and cognitive functioning. Based on structural and functional neuroimaging evidence, this study proposes an individualized intermittent theta burst stimulation (iTBS) protocol targeting the primary visual cortex (V1) and its functional pathway to the hippocampus, combined with online cognitive training. This randomized, double-blind, parallel-group, sham-controlled trial will enroll 88 patients with bipolar disorder in remission phase and allocate them to active or sham stimulation. The intervention will be delivered over 5 days, with follow-up assessments through 6 weeks. The primary outcome is change in cognitive performance as measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB). Secondary outcomes include changes in clinical symptom ratings, magnetic resonance imaging (MRI) biomarkers, and the incidence of adverse events. This study aims to evaluate the efficacy and safety of this targeted intervention and to provide evidence for precision treatment approaches to cognitive impairment in bipolar disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1: Age between 18 and 45 years; 2: Right-handed; 3: Meet the , Fifth Edition (DSM-5) criteria for bipolar disorder and are currently in a stable remission phase; 4: Hamilton Depression Rating Scale 24-item (HAMD-24) score \< 8; 5: Young Mania Rating Scale (YMRS) score \<= 7; 6: The participant and his/her legal guardian are willing to comply with the treatment procedures and provide written .
Exclusion Criteria:
1: Diagnosis of another primary psychiatric disorder judged by the investigators to be the predominant condition, with functional impairment exceeding that attributable to bipolar disorder; 2: Comorbid psychiatric disorders, including obsessive-compulsive disorder, personality disorders, anxiety spectrum disorders, intellectual disability, or substance use (dependence/abuse); 3: Inability to complete self-report symptom rating scales or the CANTAB cognitive assessment; 4: Prominent suicidal ideation (item 3 of the HAMD-24 >= 2); 5: History of severe physical illness or other medical conditions that may affect the central nervous system; 6: Neurological disorders or risk factors for seizures, such as a history of intracranial disease, head injury, abnormal electroencephalogram (EEG) findings, magnetic resonance imaging (MRI) evidence of structural brain abnormalities, or a family history of epilepsy; 8: to MRI or transcranial magnetic stimulation, such as the presence of metallic or electronic implants (e.g., intracranial metallic foreign bodies, cochlear implants, cardiac pacemakers, vascular stents); 9: Receipt of electroconvulsive therapy (ECT) within 6 months prior to study enrollment; 10: Currently undergoing transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neuromodulatory interventions; 11: Pregnant or breastfeeding women, and women of with a positive urine pregnancy test.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive active iTBS over the individualized left V1-HPC target using MRI-guided neuronavigation, delivered twice daily for 5 consecutive days (90% RMT; 1,800 pulses per session; \~10 minutes). Each stimulation session will be paired with the same online computerized pattern recall training.
Device: Active Intermittent Theta Burst Stimulation · Behavioral: Online Cognitive Training
Participants will receive sham iTBS over the individualized left V1-HPC target using MRI-guided neuronavigation, delivered twice daily for 5 consecutive days (20% RMT; all other iTBS parameters identical to the active group). Each stimulation session will be paired with the same online computerized pattern recall training.
Behavioral: Online Cognitive Training · Device: Sham Intermittent Theta Burst Stimulation
Active iTBS will be delivered using MRI-guided neuronavigation system. Participants will receive two sessions per day for 5 consecutive days. The iTBS pattern consists of bursts of three pulses at 50 Hz, repeated at 5 Hz. Each train lasts 2 s and is followed by an 8-s inter-train interval. Stimulation will be administered at 90% of the resting motor threshold (RMT), with a total of 1,800 pulses per session. Each session will last approximately 10 minutes. For each participant, the individual stimulation target will be defined within the left V1 as the subregion showing the strongest functional connectivity with the hippocampus. Target coordinates will be mapped onto each participant's native anatomical space and implemented using robot-assisted, MRI-guided neuronavigation based on the participant's T1-weighted structural MRI to ensure accurate and reproducible coil positioning across sessions.
Also known as: iTBS, Theta Burst Stimulation, Transcranial Magnetic Stimulation
Participants in both arms will complete the same computerized pattern recall training paired with each stimulation session (twice daily) throughout the 5-day iTBS intervention period. In each block, one abstract, difficult-to-verbalize target figure is presented centrally for 5 seconds for encoding. Following target offset, participants complete 15 consecutive match/non-match judgments: a sequence of visually similar probe figures is presented one at a time (each for 1500 ms with a 500-ms inter-stimulus interval), and participants indicate whether each probe is identical to the target figure. Upon completion of the 15 judgments, a new target figure is introduced and the next block begins. Task progression is self-paced; therefore, the number of blocks completed within a session may vary across participants depending on response speed. Ten parallel task versions will be used and kept consistent across sessions to align training content with each iTBS visit.
Also known as: Computerized cognitive training, Pattern recall training
Sham iTBS will be delivered over the individualized V1-HPC target using MRI-guided neuronavigation. The coil will be held perpendicular to the target scalp site and kept in contact throughout stimulation. Intensity will be set at 20% RMT, with all other iTBS parameters identical to the active group.
Cognitive performance will be assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Span (SSP)
SSP is a computerised version of the Corsi Blocks task, assessing working memory capacity. The span length ranges from 0 to 9 items, with higher scores indicating greater short-term memory capacity.
Time frame: Time Frame: Assessments will be conducted at baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
CANTAB Pattern Recognition Memory (PRM)
CANTAB PRM evaluates visual pattern recognition memory. The task comprises two sets of 12 stimuli: one assesses immediate recognition, and the other assesses delayed recognition. Higher corrects indicate better recognition memory performance.
Time frame: Time Frame: Assessments will be conducted at baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
CANTAB Rapid Visual Information Processing (RVP)
RVP assesses sustained visual attention and processing speed. Outcome indices include RVP A' (ranges from 0.00 to 1.00, with higher values indicating better target detection performance, and is derived from the hit rate P(hit) and false-alarm rate P(fa)), Total Hits (number of correct target detections), and Mean Latency (mean reaction time for correct responses).
Time frame: Assessments will be conducted at baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
CANTAB Spatial Working Memory (SWM)
SWM assesses the ability to retain spatial information and manipulate remembered locations within working memory. The error index reflects the number of times a participant returns to boxes in which a token has already been found; higher error counts indicate poorer working memory performance. The strategy score indexes the efficiency of search behavior, with higher scores reflecting a more disorganized search strategy.
Time frame: Assessments will be conducted at baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
Hamilton Depression Rating Scale 24-item (HAMD-24)
Clinician-rated measure of depressive symptom severity. Total score range 0-76; higher scores indicate more severe depressive symptoms.
Time frame: Baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
Hamilton Anxiety Rating Scale (HAMA)
Clinician-rated measure of anxiety symptom severity. Total score range 0-56; higher scores indicate more severe anxiety symptoms.
Time frame: Baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
Young Mania Rating Scale (YMRS)
Clinician-rated measure of manic symptom severity. Total score range 0-60; higher scores indicate more severe manic symptoms.
Time frame: Baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
Self-Rating Depression Scale (SDS)
Self-reported measure of depressive symptom severity. Total (raw) score range 20-80; higher scores indicate more severe depressive symptoms.
Time frame: Baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
Self-Rating Anxiety Scale (SAS)
Self-reported measure of anxiety symptom severity. Total (raw) score range 20-80; higher scores indicate more severe anxiety symptoms.
Time frame: Baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
Perceived Deficits Questionnaire-Depression (PDQ-D)
Self-reported measure of subjective cognitive difficulties (e.g., attention, memory, planning). Total score range 0-80; higher scores indicate greater perceived cognitive impairment.
Time frame: Baseline prior to randomization (T0), immediately after completion of the intervention (T1), and at 6 weeks (T2) post-intervention follow-up.
Adverse Event Report Form
Safety outcomes were assessed using an adverse event report form that captures overall AE severity (total score 0-54) and participant-rated treatment-relatedness (total score 0-72). Higher scores indicate greater AE severity and stronger perceived relatedness to the intervention, respectively.
Time frame: During the 5-day intervention period
Resting-state fMRI functional connectivity (FC) between V1 and hippocampus
Resting-state FC will be quantified as the Pearson correlation between the mean BOLD time series extracted from the individualized V1 stimulation target and the hippocampus. Higher Fisher z values indicate stronger V1-HPC coupling .
Time frame: 1 day before the intervention and within 2 days after completion of the intervention course.
Resting-state fMRI amplitude of low-frequency fluctuations (ALFF) in V1 and hippocampus
ALFF will be calculated within the V1 stimulation target and hippocampus as the amplitude of spontaneous low-frequency BOLD fluctuations. The outcome is the change in ALFF from baseline to post-intervention. Higher ALFF reflects greater amplitude of low-frequency spontaneous activity.
Time frame: 1 day before the intervention and within 2 days after completion of the intervention course.
Resting-state fMRI fractional amplitude of low-frequency fluctuations (fALFF) in V1 and hippocampus
fALFF will be calculated within the V1 stimulation target and hippocampus ROI as the ratio of low-frequency power (typically 0.01-0.10 Hz) to the total detectable frequency range of the BOLD signal. The outcome is the change in fALFF from baseline to post-intervention. fALFF ranges from 0 to 1; higher values indicate a larger fraction of low-frequency fluctuations.
Time frame: 1 day before the intervention and within 2 days after completion of the intervention course.
Resting-state fMRI regional homogeneity (ReHo) in V1 and hippocampus
ReHo will be computed within the V1 stimulation target and hippocampus as the local synchrony of BOLD time series among neighboring voxels. The outcome is the change in ReHo from baseline to post-intervention. Higher ReHo indicates stronger local synchronization.
Time frame: 1 day before the intervention and within 2 days after completion of the intervention course.
Plan to share: No — This study collects sensitive clinical, neurocognitive, and MRI data. Because the current informed consent, ethics approval, and institutional data governance do not permit external sharing of IPD. Study-level summary results will be disseminated via peer-reviewed publications.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 12 months is below that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Zhejiang University →